Commentary

Video

Hood on the Association Between BRCA Mutations and Primary Tumor Location in PDAC

Author(s):

Ryan Hood, BA, discusses a study investigating the association between BRCA1/2 pathogenic variants and primary tumor location in pancreatic cancer.

Ryan Hood, BA, MD/MPH student, University of Miami Miller School of Medicine, discusses findings from a study investigating the association between BRCA1/2 pathogenic variants, primary tumor location, and metastatic organotropism in patients with pancreatic ductal adenocarcinoma (PDAC).

This retrospective study used information from a database to evaluate patients with PDAC harboring BRCA1/2 pathogenic variants, as well as a matched control cohort of BRCA1/2 wild-type patients. Hood and colleagues found a positive connection between cancers in the body and tail of the pancreas with homologous recombination deficiency mutations, meaning that patients with BRCA1/2-mutated disease were more likely to have cancers in those areas of the pancreas, at 51.6% vs 31.0% (P < .001), Hood reports.

Furthermore, after adjustment for primary location, patients with BRCA1/2 mutations were less likely to have metastatic disease spread to the peritoneum vs control patients (odds ratio, 0.43; 95% CI, 0.21-0.89). Patients with BRCA1/2-mutated cancers in the body and tail of the pancreas had a significantly slower rate of peritoneal spread compared with those with body and tail tumors and BRCA1/2 wild-type disease (OR, 0.41; 95% CI, 0.20-0.83). However, no significant association was observed between the presence of BRCA1/2 mutations and peritoneal spread in patients with masses in the head of the pancreas (OR, 1.09; 95% CI, 0.48-2.5), he states.

Finally, using somatic sequencing data, investigators found that the presence of BRCA1/2 pathogenic variants was associated with a decreased risk of harboring a TP53 mutation (OR, 0.50; 95% CI, 0.25-0.96), particularly in patients with tumors in the body and tail of the pancreas (OR, 0.25; 95% CI, 0.07-0.74), Hood says. In total, 51% of patients with BRCA1/2 pathogenic variants had TP53 mutations vs 71% of those in the control group (P = .038). However, investigators observed no significant differences between the arms regarding KRAS mutations (BRCA1/2 arm, 83%; control arm, 86%; P = .60), SMAD4 mutations (16% vs 13%; P = .59), or CDKN2Amutations (19% vs 29%; P = .13), he concludes.

Related Videos
Kimmie Ng, MD, MPH
Marina Chiara Garassino, MD
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Rahul Banerjee, MD, FACP
Seth Wander, MD, PhD
Piotr Rutkowski, MD
Javier Martín Broto MD, PhD
Nicolas Girard, MD
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Guru P. Sonpavde, MD